Aevum Zenth Conglomerate
Consolidated Financial Report
Executive Summary
Aevum Zenth delivered strong Q3 2026 results, driven by accelerated commercialization of quantum computing infrastructure, record throughput in our autonomous logistics networks, and successful integration of 14 new subsidiaries in the APAC and EMEA regions. Total revenue reached $24.8 billion, representing an 18.2% year-over-year increase and exceeding consensus estimates by 6.4%.
Operating margins expanded to 37.6%, reflecting disciplined capital allocation, AI-driven supply chain optimization, and favorable energy trading dynamics. Cash flow from operations totaled $8.2 billion, funding $1.4 billion in strategic M&A, $920 million in share buybacks, and a $0.42 per share quarterly dividend (↑ 12% YoY).
Financial Highlights
| Metric | Q3 2026 | Q3 2025 | YoY Δ |
|---|---|---|---|
| Total Revenue | $24.82B | $21.00B | +18.2% |
| Gross Profit | $14.69B | $12.18B | +20.6% |
| Operating Income | $9.33B | $7.80B | +19.6% |
| Net Income | $6.10B | $4.99B | +22.2% |
| Diluted EPS | $2.84 | $2.38 | +19.3% |
| Free Cash Flow | $6.78B | $5.41B | +25.3% |
| Net Debt / EBITDA | 1.8x | 2.1x | -0.3x |
Divisional Performance
Aevum Energy & Power reported $5.1B revenue, driven by fusion pilot grid integration and record solar deployment in the Middle East. Operating margin: 34.2%.
Zenth Digital Systems accelerated quantum-as-a-service adoption, generating $4.8B in recurring cloud & enterprise AI revenue. Operating margin: 41.5%.
Aevum Aerospace & Defense secured three major sovereign satellite contracts and delivered first commercial hypersonic payload. Revenue: $3.9B.
Zenth Health Sciences advanced three gene-therapy candidates to Phase III, with $3.2B in pharma & medtech revenue. Operating margin: 38.9%.
Remaining 392 divisions contributed $7.82B in consolidated revenue, with logistics, real estate, and autonomous systems showing strongest growth velocity.